J. Safra Sarasin Holding AG Sells 38,033 Shares of Amgen Inc. $AMGN

J. Safra Sarasin Holding AG cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 15.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 207,680 shares of the medical research company’s stock after selling 38,033 shares during the period. Amgen comprises approximately 1.2% of J. Safra Sarasin Holding AG’s investment portfolio, making the stock its 19th biggest holding. J. Safra Sarasin Holding AG’s holdings in Amgen were worth $73,072,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in AMGN. Vanguard Group Inc. grew its position in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. State Street Corp lifted its position in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Capital World Investors lifted its position in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Amgen during the 4th quarter worth about $2,164,162,000. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on AMGN shares. Truist Financial lifted their target price on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Wells Fargo & Company raised their target price on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Finally, UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $355.73.

Amgen Stock Performance

NASDAQ:AMGN opened at $363.39 on Monday. The stock has a market cap of $196.13 billion, a P/E ratio of 25.29, a PEG ratio of 3.59 and a beta of 0.41. The stock has a 50 day simple moving average of $344.81 and a 200 day simple moving average of $349.45. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.32 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.